Composition for use in the treatment of intervertebral disc-related pain

Abstract

The present invention relates to intervertebral disc-related pain, such as low back pain, chronic low back pain, neck pain, chronic neck pain and coccygodynia. A composition for use in the treatment of intervertebral disc-related pain is provided. The composition comprises lactic acid, or a pharmaceutically acceptable salt thereof. The composition is administered into a disc space comprising the nucleus pulposus of an intervertebral disc.

1 . A composition for use in the treatment of intervertebral disc-related pain, wherein said composition comprises lactic acid, or a pharmaceutically acceptable salt thereof, wherein said composition is administered into a disc space comprising the nucleus pulposus of an intervertebral disc. 
     
     
         2 . The composition for use according to  claim 1 , wherein the composition is administered in an amount effective to increase the concentration of lactic acid, or the concentration of lactate ion from the pharmaceutically acceptable salt, in said disc space to above 12 mmol/L. 
     
     
         3 . The composition for use according to  claim 1 , wherein the concentration of lactic acid, or the concentration of lactate ion of the pharmaceutically acceptable salt, in the composition is at least 12 mmol/L. 
     
     
         4 . The composition for use according to  claim 1 , wherein the pharmaceutically acceptable salt is a lactate of any of the elements selected from the group consisting of: the alkali metals and the alkaline earth metals. 
     
     
         5 . The composition for use according to  claim 1 , wherein the pharmaceutically acceptable salt is selected from the group consisting of: ammonium lactate, choline lactate, lithium lactate, sodium lactate, potassium lactate, beryllium lactate, magnesium lactate and calcium lactate. 
     
     
         6 . The composition for use according to  claim 1 , wherein said composition is administered to the disc space of an intervertebral disc contributing to the intervertebral disc-related pain. 
     
     
         7 . The composition for use according to  claim 1 , wherein said lactic acid or a pharmaceutically salt thereof, is administered by local injection into the disc space comprising the nucleus pulposus. 
     
     
         8 . The composition for use according to  claim 1 , wherein the lactic acid is administered in a single dosage within the range of from 2 mg to 200 mg. 
     
     
         9 . The composition for use according to  claim 1 , wherein the lactic acid is administered in a single dosage within the range of from 5 mg to 200 mg. 
     
     
         10 . The composition for use according to  claim 8 , wherein said lactic acid or a pharmaceutically salt thereof, is administered at a single occasion in said single dosage. 
     
     
         11 . The composition for use according to  claim 1 , wherein said composition is in the form of an aqueous solution comprising said lactic acid or a pharmaceutically salt thereof. 
     
     
         12 . The composition for use according to  claim 1 , wherein said intervertebral disc-related pain is selected from neck pain, chronic neck pain, low back pain, and chronic low back pain. 
     
     
         13 . The composition for use according to  claim 1 , wherein said intervertebral disc-related pain is coccygodynia. 
     
     
         14 . The composition for use according to  claim 3 , wherein the concentration of lactic acid, or the concentration of lactate ion of the pharmaceutically acceptable salt, in the composition is within the range of 12 to 12000 mmol/L. 
     
     
         15 . The composition for use according to  claim 3 , wherein the concentration of lactic acid, or the concentration of lactate ion of the pharmaceutically acceptable salt, in the composition is within the range of 100 to 10000 mmol/L. 
     
     
         16 . The composition for use according to  claim 3 , wherein the concentration of lactic acid, or the concentration of lactate ion of the pharmaceutically acceptable salt, in the composition is within the range of 500 to 5000 mmol/L. 
     
     
         17 . The composition for use according to  claim 3 , wherein the concentration of lactic acid, or the concentration of lactate ion of the pharmaceutically acceptable salt, in the composition is within the range of 800 to 2000 mmol/L. 
     
     
         18 . The composition for use according to  claim 9 , wherein the lactic acid is administered in a single dosage within the range of 10 to 100 mg. 
     
     
         19 . The composition for use according to  claim 9 , wherein the lactic acid is administered in a single dosage within the range of such as from 10 to 50 mg. 
     
     
         20 . The composition for use according to  claim 9 , wherein the lactic acid is administered in a single dosage within the range of 15 to 30 mg.